Nkx-6.2 CRISPR Activation Plasmid (h): sc-403584-ACT

NKX6-2 encodes the homeobox transcription factor Nkx-6.2, a sequence-specific DNA-binding regulator that helps control lineage commitment and maturation programs in the developing central nervous system. Nkx-6.2 activity integrates with neural patterning and differentiation networks by modulating transcriptional cascades that shape cell fate decisions and downstream gene expression. In human biology, altered NKX6-2 regulation is relevant to studies of neurodevelopmental processes and myelination-associated gene programs, where transcriptional miswiring can perturb neuronal and glial maturation states. As a nuclear transcriptional regulator, Nkx-6.2 is frequently investigated in pathway mapping, developmental timing, and regulatory network analyses linking promoter/enhancer occupancy to phenotype.

Nkx-6.2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous NKX6-2 expression without altering the underlying DNA sequence.

Nkx-6.2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the NKX6-2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the NKX6-2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Nkx-6.2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native NKX6-2 locus and enabling the study of Nkx-6.2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Nkx-6.2 pathway restoration in tumor cells with silenced or reduced NKX6-2 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.